Literature DB >> 10761704

Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells.

S Ishida1, T Yamashita, U Nakaya, T Tokino.   

Abstract

Two p53-related genes, p73 and p51, were recently identified as structural homologues of the p53 tumor suppressor gene, suggesting that the roles of these two genes may be similar to those of p53, including growth suppression and induction of apoptosis. Here we show that introduction of p73 or p51 cDNAs into cultured human cancer cells suppressed colony formation in the presence of G418. We then examined the ability of various isoforms of p73 and p51 to activate transcription of a reporter gene. This assay showed that p73beta and p51A activated transcription through a consensus p53 binding sequence, while p73alpha and p51B isoforms minimally transactivated the p53 reporter gene. To characterize further the biological functions of the p53-related genes, we constructed recombinant adenoviruses containing the p73 and p51 cDNAs. Ad-p73beta and Ad-p51A induced endogenous p21 gene expression more effectively than Ad-p73alpha and Ad-p51B, respectively. To evaluate the mode of cell death induced by p53-related genes, Ad-p73 and Ad-p51 were used to infect human cancer cells. Infection of Ad-p73beta, Ad-p51A or Ad-p51B resulted in DNA fragmentation in a subset of cancer cell lines more efficiently than did infection of Ad-p53. We then examined the combined effect of each p53-related gene and the E1A oncogene in the induction of apoptosis. The E1A oncogene cooperated with p51 as well as p53 to induce apoptosis, while p73 resulted in a weak induction of apoptosis by E1A. Overall, apoptosis induction by p51B and p73alpha isoforms may be due to mechanisms other than transcriptional activation of p53-target genes. Our results suggest that p53-related genes are both similar to and different from p53 in their pathways leading to growth suppression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761704      PMCID: PMC5926321          DOI: 10.1111/j.1349-7006.2000.tb00929.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


reverse transcriptase‐polymerase chain reaction Dulbecco's modified Eagle's medium fetal bovine serum sodium dodecyl sulfate cytomegalovirus multiplicity of infection
  19 in total

1.  Definition of a consensus binding site for p53.

Authors:  W S el-Deiry; S E Kern; J A Pietenpol; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

2.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.

Authors:  A Yang; M Kaghad; Y Wang; E Gillett; M D Fleming; V Dötsch; N C Andrews; D Caput; F McKeon
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

3.  Viral oncoproteins discriminate between p53 and the p53 homolog p73.

Authors:  M C Marin; C A Jost; M S Irwin; J A DeCaprio; D Caput; W G Kaelin
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

4.  Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period.

Authors:  M Takahashi; Y Ilan; N R Chowdhury; J Guida; M Horwitz; J R Chowdhury
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

5.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.

Authors:  W J McGrory; D S Bautista; F L Graham
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

6.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

7.  p53 tagged sites from human genomic DNA.

Authors:  T Tokino; S Thiagalingam; W S el-Deiry; T Waldman; K W Kinzler; B Vogelstein
Journal:  Hum Mol Genet       Date:  1994-09       Impact factor: 6.150

Review 8.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

Review 9.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

10.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53.

Authors:  M Osada; M Ohba; C Kawahara; C Ishioka; R Kanamaru; I Katoh; Y Ikawa; Y Nimura; A Nakagawara; M Obinata; S Ikawa
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  6 in total

1.  Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.

Authors:  Hiroyuki Takai; Kazuhito Naka; Yuki Okada; Miho Watanabe; Naoki Harada; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Makoto Nakanishi; Hiroshi Suzuki; Kazuo Nagashima; Hirofumi Sawa; Kyoji Ikeda; Noboru Motoyama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

2.  Critical role of N-terminal end-localized nuclear export signal in regulation of activating transcription factor 2 (ATF2) subcellular localization and transcriptional activity.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

3.  Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

Authors:  Masood A Shammas; Paola Neri; Hemanta Koley; Ramesh B Batchu; Robert C Bertheau; Vidit Munshi; Rao Prabhala; Mariateresa Fulciniti; Yu Tzu Tai; Steven P Treon; Raj K Goyal; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

4.  Variation in the mechanical unfolding pathway of p53DBD induced by interaction with p53 N-terminal region or DNA.

Authors:  Yukinori Taniguchi; Masaru Kawakami
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

Review 5.  Activation and activities of the p53 tumour suppressor protein.

Authors:  E Bálint E; K H Vousden
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

6.  Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer.

Authors:  Reo Maruyama; Kimishige Akino; Minoru Toyota; Hiromu Suzuki; Takashi Imai; Mutsumi Ohe-Toyota; Eiichiro Yamamoto; Masanori Nojima; Tomoko Fujikane; Yasushi Sasaki; Toshiharu Yamashita; Yoshiyuki Watanabe; Hiroyoshi Hiratsuka; Koichi Hirata; Fumio Itoh; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  Carcinogenesis       Date:  2008-02-29       Impact factor: 4.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.